Viking Therapeutics closes $292.5 million convertible senior notes offering
VKTX•Viking Therapeutics closed a $258.75 million offering of 2.00% convertible senior notes due 2032, with underwriters exercising their option for an additional $33.75 million. Gross proceeds totaled $292.5 million, while net proceeds from concurrent stock and note offerings were about $547.8 million.
1. Notes offering closed
Viking Therapeutics closed its $258.75 million offering of 2.00% convertible senior notes due 2032. Underwriters fully exercised their option for an additional $33.75 million, bringing gross proceeds from the notes to $292.5 million. Net proceeds from concurrent stock and note offerings were about $547.8 million. The company earmarked funds for development of VK2735 and VK3019, working capital, research, development and general corporate purposes.
